Stocks and Investing Stocks and Investing
Wed, December 7, 2022
Tue, December 6, 2022

Matthew Harrison Maintained (ABBV) at Buy with Increased Target to $182 on, Dec 6th, 2022


Published on 2024-10-28 00:27:58 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "AbbVie Inc." (ABBV) at Buy with Increased Target from $178 to $182 on, Dec 6th, 2022.

Matthew has made no other calls on ABBV in the last 4 months.



There are 10 other peers that have a rating on ABBV. Out of the 10 peers that are also analyzing ABBV, 5 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $162 on, Monday, December 5th, 2022
  • Justin Smith of "Societe Generale" Downgraded from Strong Buy to Hold on, Tuesday, November 8th, 2022
  • Navin Jacob of "UBS" Maintained at Hold with Increased Target to $147 on, Monday, October 31st, 2022
  • Steve Chesney of "Atlantic Equities" Maintained at Hold with Decreased Target to $157 on, Monday, October 31st, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $155 on, Monday, October 31st, 2022


These are the ratings of the 5 analyists that currently disagree with Matthew


  • Trung Huynh of "Credit Suisse" Initiated at Buy and Held Target at $170 on, Friday, November 18th, 2022
  • Gary Nachman of "BMO Capital" Maintained at Buy with Decreased Target to $169 on, Monday, October 31st, 2022
  • David Risinger of "SVB Leerink" Maintained at Sell with Decreased Target to $135 on, Friday, September 30th, 2022
  • Terence Flynn of "Morgan Stanley" Reiterated at Buy and Held Target at $188 on, Wednesday, September 14th, 2022
  • Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Decreased Target to $155 on, Wednesday, August 24th, 2022
Contributing Sources